Referring now to the drawings,
As can be seen in
In the preferred mode of the device and method the implant 11 is configured in such a way as to contain medication in an internal reservoir 20 section defined by a sidewall 22 which also defines the exterior dimension of the implant 11. Using a means for disbursement of the medication from the reservoir such as an aperture 24 or permeable membrane 26, the medication 19 which will seep out of the implant 11 slowly over time. This medication 19 housed in the reservoir 20 portion of the implant 11, as it seeps therefrom, will find its way to areas in the eye 18 which are, otherwise, very difficult to reach.
In one mode of the device and method particularly preferred, once the implant 11 is drained and all the medication has left the reservoir 20 portion of the implant 11, the implant 11 will dissolve on its own (biodegradable), and be absorbed by the body. This mode would work well with either a liquid medication such as in
In an alterative embodiment, as shown in
As shown in
The dimensional aspects of the implant chosen should be well adapted to place the implant into the posterior pole of the eye 12. The dimension of the implant 11 employed should insure that it will be anchored in such a way as it will not move. The type of slow disbursement chosen and medication 19 employed should be adapted to continuously allow medication to seep into the eye 12.
Depending on the medical professional's treatment decisions the implant 11 can either dissolve over time or be refilled as in
In a particularly preferred mode of the invention, the ideal location for such an implant is within the optic nerve cup 40. This cup 40 area can appropriately hold an implant for an indefinite period of time. This is due primarily to the fact that this cup area acts as a natural glove for a properly dimensioned implant 11, such that the properly dimensioned implant 11 can be wedged into the cup 40 area so it will not require any additional anchoring mechanisms.
In a preferred embodiment of the invention herein, a doctor such as an ophthalmologist will first measure the cup 40 area within the optic nerve 16 of the eye 12 for a given patient. It is typical to find that the size of this cup area is from 300 to 500 microns, however, the extremes reach from 200 to 800 microns. As soon as the doctor determines the number of microns within the eye 12 for a given patient, the doctor will decide on the best configuration and exterior dimension for the implant 11 which will be implanted into the optic nerve head cup 40 for this patient. The doctor can select from a number of configurations yielding different exterior dimensions of the implants 11 as shown in
Once the configuration of the implant 11 is selected by the doctor, the doctor will either create the implant using his own tools (such a lathe), or he will purchase an appropriate implant from a medical device manufacturing company that is commissioned to manufacture such implants as they are needed and adapted to the shape and dimensional characteristics determined by the doctor. Such implants 11 after they are created must be appropriately sterilized before they can be implanted in the eye.
Once the doctor has made his selection (of appropriately designed, shaped, and dimensioned sterilized implants), he or she will fill the implant with the appropriate medication 19, and a surgical procedure can be performed in order to insert the implant into the optic nerve head cup 40 so the medication can seep out over time. Once again, the optic nerve 16 itself as well as the macula 14 can benefit from this medication as it will seep in the general vicinity of the posterior pole.
As described earlier, this implant will then either dissolve itself naturally (as the last of the medication leaves the implant), or the implant can be refilled by the doctor by way of a follow-up visit by the patient to the doctor's office.
Such an implant 11 as described herein works best if adapted to provide a means for medication to seep out at a predetermined level or rate and/or quantity. There are a number of ways to achieve such predetermined seepage levels, however, the preferred embodiment for this patent application is to use a biodegradable material such as gancyclovir, however, an alternative embodiment may use a semipermeable membrane material 26 instead.
As noted, and shown in
The device and method providing for an optic nerve implant and medication system shown in the drawings and described in detail herein, disclose steps in a process, arrangements of elements of particular construction, and configuration for illustrating preferred embodiments of structure and method of operation of the present invention. It is to be understood, however, that elements of different construction and configuration and different steps and process procedures and other arrangements thereof, other than those illustrated and described, may be employed for the implant device and method with the spirit of this invention.
As such, while the present invention has been described herein with reference to particular embodiments thereof, a latitude of modifications, various changes and substitutions are intended in the foregoing disclosure, and it will be appreciated that in some instance some features of the invention could be employed without a corresponding use of other features without departing from the scope of the invention as set forth in the following claims. All such changes, alternations and modifications as would occur to those skilled in the art are considered to be within the scope of this invention as broadly defined in the appended claims.
This application claims the benefit of U.S. Provisional Application 60/800,253 filed May 12, 2006. The device and methods herein provide for therapeutic methods and procedures for treating maladies associated with the optic nerve and/or the macula within the eye. More particularly, the device and method disclose an ocular implant adapted to anchor in the eye which is engageable to an eye mounted reservoir providing medication to the implant for delivery to various parts of the eye.
Number | Date | Country | |
---|---|---|---|
60800253 | May 2006 | US |